A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease
Therapeutic drug monitoring (TDM) of biologics is a rapidly evolving field. We aimed to
provide a consensus statement regarding the clinical utility of TDM for biologics in …
provide a consensus statement regarding the clinical utility of TDM for biologics in …
[HTML][HTML] Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases
Background & Aims Therapeutic drug monitoring (TDM) is widely available for biologic
therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and …
therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and …
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled …
M Ferrante, R Panaccione, F Baert, P Bossuyt… - The Lancet, 2022 - thelancet.com
Background There is a great unmet need for new therapeutics with novel mechanisms of
action for patients with Crohn's disease. The ADVANCE and MOTIVATE studies showed that …
action for patients with Crohn's disease. The ADVANCE and MOTIVATE studies showed that …
AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis
JD Feuerstein, KL Isaacs, Y Schneider… - …, 2020 - gastrojournal.org
(AGA) on the management of moderate to severe ulcerative colitis (UC). The guideline was
developed by the AGA Institute's Clinical Guidelines Committee and approved by the AGA …
developed by the AGA Institute's Clinical Guidelines Committee and approved by the AGA …
[HTML][HTML] Ulcerative colitis: Recent advances in the understanding of disease pathogenesis
RJ Porter, R Kalla, GT Ho - F1000Research, 2020 - ncbi.nlm.nih.gov
Inflammatory bowel diseases are common, complex, immune-mediated conditions with a
sharply rising global prevalence. While major advances since 2000 have provided strong …
sharply rising global prevalence. While major advances since 2000 have provided strong …
Paradoxical gastrointestinal effects of interleukin-17 blockers
M Fauny, D Moulin, F d'Amico, P Netter… - Annals of the …, 2020 - ard.bmj.com
Secukinumab, ixekizumab and brodalumab are monoclonal antibody therapies that inhibit
interleukin (IL)-17 activity and are widely used for the treatment of psoriasis, psoriatic arthritis …
interleukin (IL)-17 activity and are widely used for the treatment of psoriasis, psoriatic arthritis …
Systematic review and network meta‐analysis: first‐and second‐line biologic therapies for moderate‐severe Crohn's disease
Background There are limited data to inform positioning of agents for treating moderate‐
severe Crohn's disease (CD). Aim We assessed comparative efficacy and safety of first‐line …
severe Crohn's disease (CD). Aim We assessed comparative efficacy and safety of first‐line …
Tumor necrosis factor inhibitors for inflammatory bowel disease
OH Nielsen, MA Ainsworth - New England Journal of Medicine, 2013 - Mass Medical Soc
Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
[HTML][HTML] Etiology and management of lack or loss of response to anti–tumor necrosis factor therapy in patients with inflammatory bowel disease
The management of patients with moderate to severe inflammatory bowel disease was
transformed with the arrival of anti–tumor necrosis factor (TNF) therapy. Nevertheless, a …
transformed with the arrival of anti–tumor necrosis factor (TNF) therapy. Nevertheless, a …
AGA technical review on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease
The incidence and prevalence of Crohn's disease (CD) is rising globally. Patients with
moderate to severe CD are at high risk for needing surgery and hospitalization and for …
moderate to severe CD are at high risk for needing surgery and hospitalization and for …